# Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

> **NCT00348309** · NA · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1496 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Rosiglitazone Extended Release 2mg
- **DRUG:** Rosiglitazone Extended Release 8mg
- **OTHER:** Placebo
- **OTHER:** Donepezil

## Key facts

- **NCT ID:** NCT00348309
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-06
- **Primary completion:** 2009-01-01
- **Final completion:** 2009-01-28
- **Target enrollment:** 1496 (ACTUAL)
- **Last updated:** 2017-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00348309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00348309, "Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00348309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*